INTERVENTIONALPROTOCOL REGISTERED2022-001256-42
A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in C...
Lennox-Gastaut syndrome (LGS)
Locally preserved from EU Clinical Trials Register (EudraCT)Open EU Clinical Trials Register (EudraCT)↗last source update not reported
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- Not reported
- Enrollment
- Not reported
- Start date
- 2023-03-08
- Sponsor
- SK Life Science, Inc
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
Lennox-Gastaut syndrome (LGS)Lennox-Gastaut syndrome (LGS)
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
No structured eligibility criteria were reported.
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 461ca1ab-8d37-4212-941e-09fbca811d2f
- Retrieved
- 14/09/2026, 10:12:19
- SHA-256
- 0114b0c146b4c895c3d176be0813898bb833c0188c7a42effde91a02ce35f35d